- JP-listed companies
- Nano Holdings, Inc.
- Income statement
Nano Holdings, Inc. (4571) Income statement
Market cap
¥8.5B
P/E ratio
NANO MRNA develops RNA-based drug candidates including mRNA and siRNA therapies, then licenses them to pharmaceutical companies for late-stage development and commercialization.
| 2012/03 | 2013/03 | 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Revenue | 346 | 374 | 472 | 676 | 243 | 219 | 259 | 497 | 553 | 313 | 264 | 202 | 136 | 109 | 174 |
| Revenue growth (%) | - | ||||||||||||||
| Cost of revenue | - | - | - | 212 | 32 | 61 | 68 | 80 | 78 | 38 | 41 | 43 | 25 | 30 | 21 |
| Gross profit | - | - | - | 464 | 212 | 158 | 191 | 417 | 475 | 275 | 223 | 160 | 111 | 78 | 153 |
| Gross margin (%) | - | - | - | ||||||||||||
| Operating margin (%) | - | - | - | ||||||||||||
| Operating expenses | - | - | - | 1,572 | 2,294 | 2,870 | 5,543 | 2,219 | 1,581 | 1,578 | 2,284 | 1,406 | 975 | 834 | 1,119 |
| Operating income | - | - | - | -1,108 | -2,083 | -2,712 | -5,351 | -1,802 | -1,106 | -1,303 | -2,061 | -1,246 | -864 | -755 | -966 |
| Income before tax | -366 | -432 | -1,095 | -171 | -2,381 | -2,619 | -5,304 | -1,774 | -1,144 | -1,279 | -1,925 | -1,105 | -750 | -688 | -867 |
| Pretax margin (%) | -105.7 | -115.6 | -231.9 | -25.3 | -978.5 | -1,197.6 | -2,047.3 | -357.2 | -207 | -408.2 | -729.2 | -546.3 | -553.4 | -633.6 | -496.8 |
| Provision for income taxes | - | - | - | - | - | - | - | - | - | - | - | 2 | 2 | 3 | 3 |
| Effective tax rate (%) | - | - | - | - | - | - | - | - | - | - | - | ||||
| Net income | -398 | -484 | -1,114 | -207 | -2,537 | -2,676 | -5,417 | -1,809 | -2,010 | -2,836 | -1,882 | -1,311 | -780 | -835 | -944 |
| Earnings per share | -17.42 | -18.85 | -30.44 | -5.12 | -59.53 | -62.07 | -125.39 | -39.14 | -32.68 | -41.53 | -26.9 | -18.7 | -11.1 | -11.85 | -12.9 |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |